The FDA's psychedelic sea-change: what accelerated clinical trials for psilocybin, methylone, and ibogaine mean for mental health and neuroscience research | Boris Heifets

Last month we saw a big shift in the federal government’s approach to psychedelic medicine. Specifically, following an executive order by President Trump, the FDA announced it is fast-tracking its review of several clinical trials of psychedelic drugs for patients with mental health disorders. The executive order also directed more funds towards psychedelic research and a review of psychedelics’ status as highly restricted Schedule 1 substances. To help us understand what all this means...